Hyperglycemia, diabetes, and de novo diabetes in patients hospitalized in intensive care units for COVID-19 in Colombia: Results from a longitudinal cohort study
, , , , , , y
31 jul 2025
Acerca de este artículo
Categoría del artículo: Research Article
Publicado en línea: 31 jul 2025
Páginas: 257 - 264
Recibido: 10 jun 2024
Aceptado: 05 jun 2025
DOI: https://doi.org/10.2478/jccm-2025-0026
Palabras clave
© 2025 John Jaime Sprockel et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Fig. 1.
Fig. 2.
Fig. 3.
Laboratory Results and Outcomes
| White blood cell count (×103 cells/μL) | 11894 (9607) | 11894 (9607) | 11911 (9685) | 11870 (9670) |
| Lymphocytes (×103 cells/μL) | 982 (1626) | 905 (772) | 867 (724) | 899 (785) |
| Platelet count (×103 cells/μL) | 241723 (95848) | 241723 (95848) | 242059 (95948) | 241986 (96157) |
| Lactate (mmol/L) | 1.96 (1.78) | 1.96 (1.78) | 1.98 (1.79) | 1.96 (1.79) |
| Creatinin (mg/dL) | 0.28 (0.73) | 0.27 (0.73) | 0.29 (0.74) | 2.0 (0.74) |
| Aspartate aminotransferase (U/L) | 126 (424.8) | 126 (424.8) | 127 (429.12) | 126 (428.4) |
| Alanine aminotransferase (U/L) | 97 (235.62) | 97 (235.62) | 98 (237.91) | 93 (208.2) |
| Prothrombin time (seg) | 12 (9.13) | 12 (9.13) | 12 (9.22) | 12 (9.21) |
| Partial thromboplastin time (seg) | 28.2 (17.7) | 28.2 (17.7) | 28.2 (17.92) | 28.3 (17.92) |
| C-reactive protein (mg/L) | 18.3 (20.21) | 18.3 (20.21) | 18.4 (20.36) | 18.4 (20.34) |
| Ferritin (ng/mL) | 1054 (635.43) | 1054 (635.43) | 1058 (628.93) | 1052 (635.49) |
| D – Dimer (μg/mL) | 220 (2100) | 220 (2100) | 224 (2122) | 224 (2122) |
| Lactate dehydrogenase, U/L | 1163 (5530) | 1163 (5530) | 1163 (5582) | 1167 (5568) |
| Positive troponin, n(%) | 257 (47.0%) | 172 (50.0%) | 49 (37.0%) | 36 (54.0%) |
| PaO2/FiO2 Ratio | 103 (61.41) | 103 (61.41) | 104 (61.77) | 103 (61.68) |
| Acute Physiology And Chronic Health | ||||
| Evaluation (APACHE) II at admission | 14.58 (7.16) | 14.58 (7.16) | 14.62 (7.17) | 14.56 (7.13) |
| Sequential Organ Failure Assessment (SOFA) at admission | 5.22 (3.55) | 5.22 (3.55) | 5.21 (3.57) | 5.22 (3.54) |
| CURB-65 | 1.82 (1.03) | 1.82 (1.03) | 1.82 (1.04) | 1.81 (1.03) |
| Severe ARDS (Pa/FiO2 <100) | 341 (62.34%) | 259 (75.0%) | 77 (58.0%) | 50 (75.0%) |
| Acute Liver Injury | 60 (10.96%) | 53 (15.2%) | 7 (5.3%) | 11 (16.4%) |
| Coagulopathy | 59 (10.78%) | 46 (13.31%) | 12 (9.0%) | 13 (19.4%) |
| CNS Involvement | 50 (9.14) | 37 (11.0%) | 12 (9.0%) | 12 (18.0%) |
| Acute Myocardial Injury | 141 (25.77) | 108 (31.1%) | 30 (23.0%) | 23 (34.3%) |
| Pulmonary embolism, n (%) | 65 (11.88%) | 51 (15.0%) | 13 (10.0%) | 17 (25.3%) |
| Length of Hospital Stay, mean (SD) | 23.6 (18.45) | 23.6 (18.45) | 23.75 (18.58) | 23.68 (18.56) |
| Death, n (%) | 317 (58.0%) | 211 (61.0%) | 65 (49.0%) | 41 (61.2%) |
Results of Bivariate Analyses
| All diabetes | 0.888 | 0.6953 – 1.135 | 0.344 |
| History of diabetes | 0.881 | 0.6675 – 1.163 | 0.371 |
| 0.963 | 0.672 – 1.378 | 0.835 |
General characteristics of the population
| Female sex, n (%) | 196 (36%) | 130 (37.5%) | 62 (46.7%) | 25 (37.3%) |
| Age (years), mean (SD) | 59.8 (14.3) | 59.83 (17.0) | 60.2 (13.9) | 59.6 (14.2) |
| 20–29, n (%) | 19 (3.4%) | 17 (4.8%) | 3 (2.3%) | 3 (4.5%) |
| 30–39 | 36 (6.5%) | 29 (8.3%) | 7 (5.2%) | 3 (4.5%) |
| 40–49 | 76 (13.9%) | 65 (18.7%) | 9 (6.8%) | 7 (10.5%) |
| 50–59 | 112 (20.4%) | 84 (24.2%) | 25 (18.8%) | 19 (28.3%) |
| 60–69 | 154 (28.1%) | 103 (29.6%) | 49 (36.8%) | 26 (39.0%) |
| 70–79 | 112 (20.4%) | 77 (22.2%) | 31 (23.3%) | 15 (22.4%) |
| 80–89 | 37 (6.7%) | 28 (8.06%) | 9 (6.8%) | 4 (6.0%) |
| <=90 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Obesity, n (%) | 154 (28.1%) | 112 (32.3%) | 41 (30.8%) | 20 (30.0%) |
| Hypertension | 237 (43.3%) | 140 (40.3%) | 93 (70.0%) | 28 (42.0%) |
| Chronic Heart Disease (excluding Hypertension) | 60 (19.9%) | 38 (11.0%) | 22 (16.5%) | 8 (12.0%) |
| Chronic kidney disease | 22 (4.0%) | 11 (3.2%) | 11 (8.3%) | 1 (1.5%) |
| Smoking | 131 (23.9%) | 99 (28.5%) | 31 (23.3%) | 13 (19.4%) |
| Chronic lung disease | 107 (19.5%) | 72 (20.7%) | 34 (25.6%) | 14 (21.0%) |
| Chronic Neurological Disease or Dementia | 25 (4.5%) | 16 (4.6%) | 9 (6.8%) | 3 (4.5%) |
| Human Immunodeficiency Virus | 1 (0.18%) | 1 (0.3%) | 0 (0%) | 0 (0%) |
| Autoimmune disease | 6 (1.09%) | 6 (1.7%) | 0 (0%) | 0 (0%) |
| Cancer | 15 (2.74%) | 9 (2.6%) | 6 (4.5%) | 3 (4.5%) |
| Chronic liver disease | 6 (1.09%) | 5 (1.5%) | 1 (0.8%) | 1 (1.5%) |
| Symptom duration before ICU (days), mean (SD) | 8 (4.23) | 8 (4.23) | 8 (4.13) | 8 (4.23) |